Details of the Drug

General Information of Drug (ID: DM5KYPJ)

Drug Name
Butorphanol
Synonyms
Beforal; Butorfanol; Butorphanolum; Moradol; Stadol; Butorphanol tartrate; BC-2627; Beforal (TN); Butorfanol [INN-Spanish]; Butorphanolum [INN-Latin]; L-BC 2627; Moradol (TN); Butorphanol (USAN/INN); Butorphanol [USAN:BAN:INN]; Levo-BC-2627; (-)-17-(Cyclobutylmethyl)morphinan-3,14-diol; (-)-N-cyclobutylmethyl-3,14-dihydroxymorphinan; (-)-butorphanol; 17-(CYCLOBUTYLMETHYL)MORPHINAN-3,14-DIOL
Indication
Disease Entry ICD 11 Status REF
Pain MG30-MG3Z Approved [1]
Therapeutic Class
Analgesics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 327.5
Logarithm of the Partition Coefficient (xlogp) 3.8
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [2]
Clearance
The drug present in the plasma can be removed from the body at the rate of 41 mL/min/kg [3]
Elimination
2% of drug is excreted from urine in the unchanged form [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 18 hours [3]
Metabolism
The drug is metabolized via the liver []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.81534 micromolar/kg/day [4]
Unbound Fraction
The unbound fraction of drug in plasma is 0.17% [3]
Vd
The volume of distribution (Vd) of drug is 305-901 L []
Water Solubility
The ability of drug to dissolve in water is measured as 2 mg/mL [2]
Chemical Identifiers
Formula
C21H29NO2
IUPAC Name
(1S,9R,10S)-17-(cyclobutylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene-4,10-diol
Canonical SMILES
C1CC[C@]2([C@H]3CC4=C([C@]2(C1)CCN3CC5CCC5)C=C(C=C4)O)O
InChI
InChI=1S/C21H29NO2/c23-17-7-6-16-12-19-21(24)9-2-1-8-20(21,18(16)13-17)10-11-22(19)14-15-4-3-5-15/h6-7,13,15,19,23-24H,1-5,8-12,14H2/t19-,20+,21-/m1/s1
InChIKey
IFKLAQQSCNILHL-QHAWAJNXSA-N
Cross-matching ID
PubChem CID
5361092
ChEBI ID
CHEBI:3242
CAS Number
42408-82-2
DrugBank ID
DB00611
TTD ID
D0X9RG
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Opioid receptor delta (OPRD1) TT27RFC OPRD_HUMAN Agonist [5]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Mu-type opioid receptor (OPRM1) OT16AAT8 OPRM_HUMAN Gene/Protein Processing [6]
Protein kinase C delta type (PRKCD) OTSEH90E KPCD_HUMAN Protein Interaction/Cellular Processes [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Pain
ICD Disease Classification MG30-MG3Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Opioid receptor delta (OPRD1) DTT OPRD1 5.52E-01 0.03 0.23
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Butorphanol
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Pentazocine DM1XBHS Major Additive CNS depression effects by the combination of Butorphanol and Pentazocine. Pain [MG30-MG3Z] [8]
Dextropropoxyphene DM23HCX Major Additive CNS depression effects by the combination of Butorphanol and Dextropropoxyphene. Pain [MG30-MG3Z] [9]
Oxymorphone DM65AGJ Major Additive CNS depression effects by the combination of Butorphanol and Oxymorphone. Pain [MG30-MG3Z] [8]
Levorphanol DMGS80V Major Additive CNS depression effects by the combination of Butorphanol and Levorphanol. Pain [MG30-MG3Z] [8]
Dezocine DMJDB0Y Major Additive CNS depression effects by the combination of Butorphanol and Dezocine. Pain [MG30-MG3Z] [8]
Flavoxate DMKV4NL Moderate Additive antimotility effects by the combination of Butorphanol and Flavoxate. Pain [MG30-MG3Z] [10]
Nalbuphine DMOSQGU Major Additive hypotensive effects by the combination of Butorphanol and Nalbuphine. Pain [MG30-MG3Z] [8]
Buprenorphine DMPRI8G Major Additive CNS depression effects by the combination of Butorphanol and Buprenorphine. Pain [MG30-MG3Z] [8]
Hydrocodone DMQ2JO5 Major Additive hypotensive effects by the combination of Butorphanol and Hydrocodone. Pain [MG30-MG3Z] [8]
⏷ Show the Full List of 9 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Butorphanol (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Metreleptin DM1NOEK Moderate Increased metabolism of Butorphanol caused by Metreleptin mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [11]
Ivosidenib DM8S6T7 Major Increased metabolism of Butorphanol caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [12]
Arn-509 DMT81LZ Major Increased metabolism of Butorphanol caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [12]
Oliceridine DM6MDCF Major Additive hypotensive effects by the combination of Butorphanol and Oliceridine. Acute pain [MG31] [8]
Scopolamine DMOM8AL Moderate Additive antimotility effects by the combination of Butorphanol and Scopolamine. Addictive disorder [6C50-6C5Z] [10]
Mitotane DMU1GX0 Major Increased metabolism of Butorphanol caused by Mitotane mediated induction of CYP450 enzyme. Adrenal cancer [2D11] [12]
Dronedarone DMA8FS5 Major Decreased metabolism of Butorphanol caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [13]
Clorazepate DMC3JST Major Additive CNS depression effects by the combination of Butorphanol and Clorazepate. Anxiety disorder [6B00-6B0Z] [14]
Methylphenobarbital DMDSWAG Major Additive CNS depression effects by the combination of Butorphanol and Methylphenobarbital. Anxiety disorder [6B00-6B0Z] [15]
Chlormezanone DMTWUXR Major Additive CNS depression effects by the combination of Butorphanol and Chlormezanone. Anxiety disorder [6B00-6B0Z] [16]
Oxazepam DMXNZM4 Major Additive CNS depression effects by the combination of Butorphanol and Oxazepam. Anxiety disorder [6B00-6B0Z] [16]
Posaconazole DMUL5EW Major Decreased metabolism of Butorphanol caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [13]
Desipramine DMT2FDC Moderate Additive CNS depression effects by the combination of Butorphanol and Desipramine. Attention deficit hyperactivity disorder [6A05] [17]
Oritavancin DM28D05 Moderate Increased metabolism of Butorphanol caused by Oritavancin mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [11]
Dalfopristin DM4LTKV Major Decreased metabolism of Butorphanol caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [13]
Clarithromycin DM4M1SG Major Decreased metabolism of Butorphanol caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [13]
Troleandomycin DMUZNIG Major Decreased metabolism of Butorphanol caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [13]
Telithromycin DMZ4P3A Major Decreased metabolism of Butorphanol caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [13]
Cariprazine DMJYDVK Major Additive CNS depression effects by the combination of Butorphanol and Cariprazine. Bipolar disorder [6A60] [16]
Pexidartinib DMS2J0Z Major Increased metabolism of Butorphanol caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [12]
Loperamide DMOJZQ9 Moderate Additive CNS depression effects by the combination of Butorphanol and Loperamide. Bowel habit change [ME05] [18]
Tucatinib DMBESUA Major Decreased metabolism of Butorphanol caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [13]
Phenylbutazone DMAYL0T Moderate Increased metabolism of Butorphanol caused by Phenylbutazone mediated induction of CYP450 enzyme. Chronic pain [MG30] [11]
Dihydrocodeine DMB0FWL Major Additive hypotensive effects by the combination of Butorphanol and Dihydrocodeine. Chronic pain [MG30] [8]
Levomilnacipran DMV26S8 Moderate Additive serotonergic effects by the combination of Butorphanol and Levomilnacipran. Chronic pain [MG30] [17]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Butorphanol and Olopatadine. Conjunctiva disorder [9A60] [19]
Propofol DMB4OLE Moderate Additive CNS depression effects by the combination of Butorphanol and Propofol. Corneal disease [9A76-9A78] [20]
Mifepristone DMGZQEF Major Decreased metabolism of Butorphanol caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [13]
Lumacaftor DMCLWDJ Major Increased metabolism of Butorphanol caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [21]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Butorphanol and Ethanol. Cystitis [GC00] [22]
MK-8228 DMOB58Q Major Decreased metabolism of Butorphanol caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [13]
Aprepitant DM053KT Major Decreased metabolism of Butorphanol caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [13]
Sertraline DM0FB1J Moderate Additive CNS depression effects by the combination of Butorphanol and Sertraline. Depression [6A70-6A7Z] [17]
Trimipramine DM1SC8M Moderate Additive CNS depression effects by the combination of Butorphanol and Trimipramine. Depression [6A70-6A7Z] [17]
Cyclobenzaprine DM1YBRM Major Additive CNS depression effects by the combination of Butorphanol and Cyclobenzaprine. Depression [6A70-6A7Z] [16]
Vilazodone DM4LECQ Moderate Additive CNS depression effects by the combination of Butorphanol and Vilazodone. Depression [6A70-6A7Z] [17]
Nefazodone DM4ZS8M Major Decreased metabolism of Butorphanol caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [13]
Paroxetine DM5PVQE Moderate Additive serotonergic effects by the combination of Butorphanol and Paroxetine. Depression [6A70-6A7Z] [17]
Vortioxetine DM6F1PU Moderate Additive CNS depression effects by the combination of Butorphanol and Vortioxetine. Depression [6A70-6A7Z] [17]
Milnacipran DMBFE74 Moderate Additive serotonergic effects by the combination of Butorphanol and Milnacipran. Depression [6A70-6A7Z] [17]
Escitalopram DMFK9HG Moderate Additive serotonergic effects by the combination of Butorphanol and Escitalopram. Depression [6A70-6A7Z] [17]
Desvenlafaxine DMHD4PE Moderate Additive CNS depression effects by the combination of Butorphanol and Desvenlafaxine. Depression [6A70-6A7Z] [17]
OPC-34712 DMHG57U Major Additive CNS depression effects by the combination of Butorphanol and OPC-34712. Depression [6A70-6A7Z] [16]
Clomipramine DMINRKW Moderate Additive CNS depression effects by the combination of Butorphanol and Clomipramine. Depression [6A70-6A7Z] [17]
Trazodone DMK1GBJ Moderate Additive CNS depression effects by the combination of Butorphanol and Trazodone. Depression [6A70-6A7Z] [17]
Doxepin DMPI98T Moderate Additive serotonergic effects by the combination of Butorphanol and Doxepin. Depression [6A70-6A7Z] [17]
Maprotiline DMPWB7T Moderate Additive serotonergic effects by the combination of Butorphanol and Maprotiline. Depression [6A70-6A7Z] [17]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Butorphanol and Esketamine. Depression [6A70-6A7Z] [23]
Mepenzolate DM8YU2F Moderate Additive antimotility effects by the combination of Butorphanol and Mepenzolate. Digestive system disease [DE2Z] [10]
5-hydroxy-L-tryptophan DMDWZGJ Moderate Additive serotonergic effects by the combination of Butorphanol and 5-hydroxy-L-tryptophan. Discovery agent [N.A.] [17]
Oxybutynine DMJPBAX Moderate Additive antimotility effects by the combination of Butorphanol and Oxybutynine. Discovery agent [N.A.] [10]
Heroin diacetylmorphine DMDBWHY Major Additive CNS depression effects by the combination of Butorphanol and Heroin diacetylmorphine. Dissociative neurological symptom disorder [6B60] [14]
Diazepam DM08E9O Major Additive CNS depression effects by the combination of Butorphanol and Diazepam. Epilepsy/seizure [8A61-8A6Z] [16]
Primidone DM0WX6I Major Increased metabolism of Butorphanol caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [10]
Felbamate DM1V5ZS Moderate Increased metabolism of Butorphanol caused by Felbamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [11]
Oxcarbazepine DM5PU6O Major Increased metabolism of Butorphanol caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [23]
Gabapentin DM6T924 Major Additive CNS depression effects by the combination of Butorphanol and Gabapentin. Epilepsy/seizure [8A61-8A6Z] [24]
Cenobamate DM8KLU9 Major Increased metabolism of Butorphanol caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [12]
Stiripentol DMMSDOY Major Decreased metabolism of Butorphanol caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [13]
Fosphenytoin DMOX3LB Major Increased metabolism of Butorphanol caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [23]
Clonazepam DMTO13J Major Additive CNS depression effects by the combination of Butorphanol and Clonazepam. Epilepsy/seizure [8A61-8A6Z] [16]
Rufinamide DMWE60C Moderate Increased metabolism of Butorphanol caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [11]
Phenobarbital DMXZOCG Major Increased metabolism of Butorphanol caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [10]
Eslicarbazepine DMZREFQ Major Increased metabolism of Butorphanol caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [23]
Dantrolene DM1D8XY Major Additive CNS depression effects by the combination of Butorphanol and Dantrolene. Fever [MG26] [16]
Tazemetostat DMWP1BH Moderate Increased metabolism of Butorphanol caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [11]
Solifenacin DMG592Q Moderate Additive antimotility effects by the combination of Butorphanol and Solifenacin. Functional bladder disorder [GC50] [10]
Tolterodine DMSHPW8 Moderate Additive antimotility effects by the combination of Butorphanol and Tolterodine. Functional bladder disorder [GC50] [10]
Itraconazole DMCR1MV Major Decreased metabolism of Butorphanol caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [13]
Miconazole DMPMYE8 Moderate Decreased metabolism of Butorphanol caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [25]
Ketoconazole DMPZI3Q Major Decreased metabolism of Butorphanol caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [13]
Propantheline DM2EN6G Moderate Additive antimotility effects by the combination of Butorphanol and Propantheline. Gastric ulcer [DA60] [10]
Sulfinpyrazone DMEV954 Moderate Increased metabolism of Butorphanol caused by Sulfinpyrazone mediated induction of CYP450 enzyme. Gout [FA25] [11]
Boceprevir DMBSHMF Major Decreased metabolism of Butorphanol caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [13]
Telaprevir DMMRV29 Major Decreased metabolism of Butorphanol caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [13]
Rifampin DMA8J1G Major Increased metabolism of Butorphanol caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [21]
Rifapentine DMCHV4I Major Increased metabolism of Butorphanol caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [12]
Delavirdine DM3NF5G Major Decreased metabolism of Butorphanol caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [13]
Cobicistat DM6L4H2 Major Decreased metabolism of Butorphanol caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [13]
Efavirenz DMC0GSJ Major Increased metabolism of Butorphanol caused by Efavirenz mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [12]
Saquinavir DMG814N Major Decreased metabolism of Butorphanol caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [13]
Etravirine DMGV8QU Major Increased metabolism of Butorphanol caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [12]
Amprenavir DMLMXE0 Major Decreased metabolism of Butorphanol caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [13]
Darunavir DMN3GCH Major Decreased metabolism of Butorphanol caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [13]
Atazanavir DMSYRBX Major Decreased metabolism of Butorphanol caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [13]
Verapamil DMA7PEW Major Decreased metabolism of Butorphanol caused by Verapamil mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [13]
Conivaptan DM1V329 Major Decreased metabolism of Butorphanol caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [13]
Lesinurad DMUR64T Moderate Increased metabolism of Butorphanol caused by Lesinurad mediated induction of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [11]
Belladonna DM2RBWK Moderate Additive antimotility effects by the combination of Butorphanol and Belladonna. Infectious gastroenteritis/colitis [1A40] [10]
Suvorexant DM0E6S3 Major Additive CNS depression effects by the combination of Butorphanol and Suvorexant. Insomnia [7A00-7A0Z] [16]
Amobarbital DM0GQ8N Major Increased metabolism of Butorphanol caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [10]
Ramelteon DM7IW9J Major Additive CNS depression effects by the combination of Butorphanol and Ramelteon. Insomnia [7A00-7A0Z] [16]
Flurazepam DMAL4G0 Major Additive CNS depression effects by the combination of Butorphanol and Flurazepam. Insomnia [7A00-7A0Z] [16]
Triazolam DMETYK5 Major Additive CNS depression effects by the combination of Butorphanol and Triazolam. Insomnia [7A00-7A0Z] [16]
Zaleplon DMGFWSM Major Additive CNS depression effects by the combination of Butorphanol and Zaleplon. Insomnia [7A00-7A0Z] [16]
Propiomazine DMKY8V1 Major Additive CNS depression effects by the combination of Butorphanol and Propiomazine. Insomnia [7A00-7A0Z] [16]
Tasimelteon DMLOQ1V Major Additive CNS depression effects by the combination of Butorphanol and Tasimelteon. Insomnia [7A00-7A0Z] [16]
Paraldehyde DMOC1BX Major Additive CNS depression effects by the combination of Butorphanol and Paraldehyde. Insomnia [7A00-7A0Z] [16]
ITI-007 DMUQ1DO Major Additive CNS depression effects by the combination of Butorphanol and ITI-007. Insomnia [7A00-7A0Z] [16]
Quazepam DMY4D87 Major Additive CNS depression effects by the combination of Butorphanol and Quazepam. Insomnia [7A00-7A0Z] [16]
Estazolam DMZGXUM Major Additive CNS depression effects by the combination of Butorphanol and Estazolam. Insomnia [7A00-7A0Z] [16]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Butorphanol and Polyethylene glycol. Irritable bowel syndrome [DD91] [26]
Clidinium DMUMQZ0 Moderate Additive antimotility effects by the combination of Butorphanol and Clidinium. Irritable bowel syndrome [DD91] [10]
Dicyclomine DMZSDGX Moderate Additive antimotility effects by the combination of Butorphanol and Dicyclomine. Irritable bowel syndrome [DD91] [10]
Remimazolam DMLVSYX Major Additive CNS depression effects by the combination of Butorphanol and Remimazolam. Labour/delivery anaesthesia complication [JB0C] [16]
Crizotinib DM4F29C Major Decreased metabolism of Butorphanol caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [13]
Brigatinib DM7W94S Moderate Increased metabolism of Butorphanol caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [11]
PF-06463922 DMKM7EW Major Increased metabolism of Butorphanol caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [12]
Idelalisib DM602WT Major Decreased metabolism of Butorphanol caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [13]
Vemurafenib DM62UG5 Moderate Increased metabolism of Butorphanol caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [11]
Dabrafenib DMX6OE3 Major Increased metabolism of Butorphanol caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [12]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Butorphanol and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [27]
Almogran DM7I64Z Moderate Additive CNS depression effects by the combination of Butorphanol and Almogran. Migraine [8A80] [17]
Frovatriptan DM7RE8P Moderate Additive CNS depression effects by the combination of Butorphanol and Frovatriptan. Migraine [8A80] [17]
Rizatriptan DMDJMA3 Moderate Additive CNS depression effects by the combination of Butorphanol and Rizatriptan. Migraine [8A80] [17]
Naratriptan DMO50U2 Moderate Additive serotonergic effects by the combination of Butorphanol and Naratriptan. Migraine [8A80] [17]
Sumatriptan DMVYXR8 Moderate Additive CNS depression effects by the combination of Butorphanol and Sumatriptan. Migraine [8A80] [17]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Butorphanol and Lasmiditan. Migraine [8A80] [28]
Exjade DMHPRWG Moderate Increased metabolism of Butorphanol caused by Exjade mediated induction of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [11]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Butorphanol and Flibanserin. Mood disorder [6A60-6E23] [29]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Butorphanol and Thalidomide. Multiple myeloma [2A83] [30]
Rifabutin DM1YBHK Major Increased metabolism of Butorphanol caused by Rifabutin mediated induction of CYP450 enzyme. Mycobacterium infection [1B10-1B21] [12]
Imatinib DM7RJXL Major Decreased metabolism of Butorphanol caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [13]
Prasugrel DM7MT6E Moderate Altered absorption of Butorphanol due to GI dynamics variation caused by Prasugrel. Myocardial infarction [BA41-BA43] [31]
Modafinil DMYILBE Major Increased metabolism of Butorphanol caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [12]
Netupitant DMEKAYI Major Decreased metabolism of Butorphanol caused by Netupitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [13]
Metoclopramide DMFA5MY Moderate Additive antimotility effects by the combination of Butorphanol and Metoclopramide. Nausea/vomiting [MD90] [32]
Granisetron DMIUW25 Moderate Additive CNS depression effects by the combination of Butorphanol and Granisetron. Nausea/vomiting [MD90] [17]
Dolasetron DMMG26Z Moderate Additive CNS depression effects by the combination of Butorphanol and Dolasetron. Nausea/vomiting [MD90] [17]
Ondansetron DMOTQ1I Moderate Additive serotonergic effects by the combination of Butorphanol and Ondansetron. Nausea/vomiting [MD90] [17]
Bupropion DM5PCS7 Major Increased risk of lowers seizure threshold by the combination of Butorphanol and Bupropion. Nicotine use disorder [6C4A] [33]
Sibutramine DMFJTDI Moderate Additive CNS depression effects by the combination of Butorphanol and Sibutramine. Obesity [5B80-5B81] [17]
Dexfenfluramine DMJ7YDS Moderate Additive CNS depression effects by the combination of Butorphanol and Dexfenfluramine. Obesity [5B80-5B81] [17]
Levomethadyl Acetate DM06HG5 Major Additive hypotensive effects by the combination of Butorphanol and Levomethadyl Acetate. Opioid use disorder [6C43] [8]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Butorphanol and Apraclonidine. Optic nerve disorder [9C40] [34]
Biperiden DME78OA Moderate Additive CNS depression effects by the combination of Butorphanol and Biperiden. Parkinsonism [8A00] [35]
Pimavanserin DMR7IVC Major Additive CNS depression effects by the combination of Butorphanol and Pimavanserin. Parkinsonism [8A00] [16]
Orphenadrine DMW542E Major Additive CNS depression effects by the combination of Butorphanol and Orphenadrine. Parkinsonism [8A00] [16]
Methylscopolamine DM5VWOB Moderate Additive antimotility effects by the combination of Butorphanol and Methylscopolamine. Peptic ulcer [DA61] [10]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Butorphanol caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [13]
Enzalutamide DMGL19D Major Increased metabolism of Butorphanol caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [12]
Fluphenazine DMIT8LX Major Additive CNS depression effects by the combination of Butorphanol and Fluphenazine. Psychotic disorder [6A20-6A25] [36]
Dexamethasone DMMWZET Major Increased metabolism of Butorphanol caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [12]
Quetiapine DM1N62C Major Additive CNS depression effects by the combination of Butorphanol and Quetiapine. Schizophrenia [6A20] [36]
Mesoridazine DM2ZGAN Major Additive CNS depression effects by the combination of Butorphanol and Mesoridazine. Schizophrenia [6A20] [36]
Thioridazine DM35M8J Major Additive CNS depression effects by the combination of Butorphanol and Thioridazine. Schizophrenia [6A20] [16]
Aripiprazole DM3NUMH Major Additive CNS depression effects by the combination of Butorphanol and Aripiprazole. Schizophrenia [6A20] [16]
Iloperidone DM6AUFY Major Additive CNS depression effects by the combination of Butorphanol and Iloperidone. Schizophrenia [6A20] [16]
Paliperidone DM7NPJS Major Additive CNS depression effects by the combination of Butorphanol and Paliperidone. Schizophrenia [6A20] [16]
Perphenazine DMA4MRX Major Additive CNS depression effects by the combination of Butorphanol and Perphenazine. Schizophrenia [6A20] [16]
Molindone DMAH70G Major Additive CNS depression effects by the combination of Butorphanol and Molindone. Schizophrenia [6A20] [16]
Thiothixene DMDINC4 Major Additive CNS depression effects by the combination of Butorphanol and Thiothixene. Schizophrenia [6A20] [36]
Trifluoperazine DMKBYWI Major Additive CNS depression effects by the combination of Butorphanol and Trifluoperazine. Schizophrenia [6A20] [16]
Risperidone DMN6DXL Major Additive CNS depression effects by the combination of Butorphanol and Risperidone. Schizophrenia [6A20] [16]
Asenapine DMSQZE2 Major Additive CNS depression effects by the combination of Butorphanol and Asenapine. Schizophrenia [6A20] [16]
Pimozide DMW83TP Major Additive CNS depression effects by the combination of Butorphanol and Pimozide. Schizophrenia [6A20] [16]
Fentanyl DM8WAHT Major Additive CNS depression effects by the combination of Butorphanol and Fentanyl. Sensation disturbance [MB40] [8]
Voxelotor DMCS6M5 Major Decreased metabolism of Butorphanol caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [13]
Telotristat ethyl DMDIYFZ Major Increased metabolism of Butorphanol caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [21]
Armodafinil DMGB035 Major Increased metabolism of Butorphanol caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [12]
LEE011 DMMX75K Major Decreased metabolism of Butorphanol caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [13]
Brilinta DMBR01X Moderate Altered absorption of Butorphanol due to GI dynamics variation caused by Brilinta. Thrombosis [DB61-GB90] [31]
Clopidogrel DMOL54H Moderate Altered absorption of Butorphanol due to GI dynamics variation caused by Clopidogrel. Thrombosis [DB61-GB90] [31]
Tizanidine DMR2IQ4 Major Additive CNS depression effects by the combination of Butorphanol and Tizanidine. Tonus and reflex abnormality [MB47] [16]
Elagolix DMB2C0E Major Increased metabolism of Butorphanol caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [12]
⏷ Show the Full List of 165 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7591).
2 BDDCS applied to over 900 drugs
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5 Butorphanol: effects of a prototypical agonist-antagonist analgesic on kappa-opioid receptors. J Pharmacol Sci. 2005 Jun;98(2):109-16.
6 In vitro functional characterization of a panel of non-fentanyl opioid new psychoactive substances. Arch Toxicol. 2020 Nov;94(11):3819-3830. doi: 10.1007/s00204-020-02855-7. Epub 2020 Jul 31.
7 Non-canonical Opioid Signaling Inhibits Itch Transmission in the Spinal Cord of Mice. Cell Rep. 2018 Apr 17;23(3):866-877. doi: 10.1016/j.celrep.2018.03.087.
8 Product Information. Buprenex (buprenorphine). Reckitt and Colman Pharmaceutical, Richmond, VA.
9 Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]
10 Product Information. Apadaz (acetaminophen-benzhydrocodone). KemPharm, Inc, Coralville, IA.
11 Altice FL, Friedland GH, Cooney EL "Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone." AIDS 13 (1999): 957-62. [PMID: 10371177]
12 Canadian Pharmacists Association.
13 Product Information. Butorphanol Tartrate (butorphanol). Apotex Corporation, Weston, FL.
14 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
15 Liu S-J, Wang RI "Case report of barbiturate-induced enhancement of methadone metabolism and withdrawal syndrome." Am J Psychiatry 141 (1984): 1287-8. [PMID: 6486271]
16 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
17 Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
18 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
19 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
20 Gill SS, Wright EM, Reilly CS "Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study." Br J Anaesth 65 (1990): 760-5. [PMID: 2265045]
21 Product Information. Mycobutin (rifabutin). Pharmacia and Upjohn, Kalamazoo, MI.
22 Sturner WQ, Garriott JC "Deaths involving propoxyphene: a study of 41 cases over a two-year period." JAMA 223 (1973): 1125-30. [PMID: 4739371]
23 Cerner Multum, Inc. "Australian Product Information.".
24 Eckhardt K, Ammon S, Hofmann U, Riebe A, Gugeler N, Mikus G "Gabapentin enhances the analgesic effect of morphine in healthy volunteers." Anesth Analg 91 (2000): 185-91. [PMID: 10866910]
25 Product Information. ORAVIG (miconazole). Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ.
26 Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
27 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
28 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
29 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
30 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
31 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
32 Product Information. Reglan (metoclopramide). Wyeth-Ayerst Laboratories, Philadelphia, PA.
33 Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
34 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
35 Product Information. Artane (trihexyphenidyl). Lederle Laboratories, Wayne, NJ.
36 Cerner Multum, Inc. "Canadian Product Information.".